From the March 27, 2020, edition of Fox News' The Ingraham Angle

LAURA INGRAHAM (HOST): Now, joining me now is Adm. Brett Giroir, who is the White House coronavirus task force member, assistant secretary for Health at HHS. Admiral, I need to ask you about this brand new study. I know you're not an epidemiologist, but you just heard me talk about it. It's not controlled, but it is clear from this -- the renowned epidemiologist and his team in Marseille -- that this hydroxy-azithro combo seems to be working. So, why are doctors and nurses and pharmacists today getting mixed messages, at times, from the administration on the need for a controlled study?

BRETT GIROIR (WHITE HOUSE CORONAVIRUS TASK FORCE): Well, thank you, Laura. It's great to be here. I don't think there is mixed messages at all. In order to be absolutely certain that the drug combination works or one of the other drugs work, sure, you need a controlled study. But hydroxychloroquine and chloroquine are both approved medications in the United States. And it is perfectly reasonable for a physician with a patient, particularly one being sick, to prescribe that. And as you described, the study that was published tonight was on 80 patients. It was not controlled. But it's again another piece of suggestive evidence that hydroxychloroquine or its related drug, chloroquine, has antiviral properties, and we need to look at that seriously.

INGRAHAM: But this is where you see this -- the tension, Admiral, in the medical community. People are not sure what to do because you have governors issuing these edicts. I mean, it's scary for these physicians and pharmacists, saying, you may not administer this in an off-label use manner if you're not part of a controlled study. And I'm talking to infectious disease doctors every day and from around the world, not just in the United States. This is their go-to combo in most patients. Period.

GIROIR: You have to understand that medicines are used off-label every day in this country. And that doesn't mean it's unsafe. That just means that it hasn't gone through the 10 years of study to be absolutely approved by the FDA. And it's all about risk-benefit.